CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Maintenance of remission in patients with ulcerative colitis with once- or twice-daily MMX™ mesalazine: results of an international multicentre randomised trial
DOI 10.1055/s-0028-1089403
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Schreiber
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: MMX Multi Matrix System® (MMX) mesalazine (MEZAVANT™; MEZAVANT™ XL [UK and Ireland]; LIALDA™ [USA]) is a once daily, high-strength (1.2g/tablet), prolonged-release formulation of 5-aminosalicylic acid (5-ASA). In this study, the safety and efficacy of MMX mesalazine when dosed once or twice daily, was evaluated in patients whose ulcerative colitis (UC) was in remission. Methods: Patients enrolled into…
Zitieren
Zitierempfehlung
S Schreiber (2008) Maintenance of remission in patients with ulcerative colitis with once- or twice-daily MMX™ mesalazine: results of an international multicentre randomised trial. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0028-1089403
Mit CareLit weiterarbeiten